Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

Mohamed A Abd El Aziz; Antonio Facciorusso; Tarek Nayfeh; Samer Saadi; Mohamed Elnaggar; Christian Cotsoglou; Rodolfo Sacco

doi:10.3390/vaccines8040616

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

Vaccines (Basel). 2020 Oct 19;8(4):616. doi: 10.3390/vaccines8040616.

Authors

Mohamed A Abd El Aziz¹, Antonio Facciorusso², Tarek Nayfeh³, Samer Saadi³, Mohamed Elnaggar⁴, Christian Cotsoglou⁵, Rodolfo Sacco^{2

6}

Affiliations

¹ Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
² Gastroenterology Unit, Department of Medical Sciences, Ospedali Riuniti di Foggia, 71122 Foggia, Italy.
³ Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN 55905, USA.
⁴ Department of Internal Medicine, Reno School of Medicine, University of Nevada, Las Vegas, NV 1155, USA.
⁵ General Surgery Department, ASST-Vimercate, 20871 Vimercate, Italy.
⁶ Gastroenterology Unit, Department of Medical Sciences, Ospedali Riuniti di Foggia, Viale Pinto, 1, 71100 Foggia, Italy.

Abstract

Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited therapeutic options. One of these options is immune checkpoint inhibitors. The aim of this study is to comprehensively review the efficacy and safety of immune checkpoint inhibitors for patients with HCC.

Keywords: CPI; HCC; immunotherapy; progression; survival.

Publication types

Review